Isis Books Kynamro Milestone; Seeks Partners For Other Pipeline Assets
This article was originally published in The Pink Sheet Daily
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.
You may also be interested in...
It’s been a long haul, but Sanofi’s Genzyme business unit and Isis have submitted their NDA for a drug that helps lower cholesterol levels in high-risk patients with a rare genetic cardiovascular disease that doesn’t respond well to statins.
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.